Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.56 USD 6.63% Market Closed
Market Cap: 554.4m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Interest Income Expense
$7.4m
CAGR 3-Years
245%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Interest Income Expense
-$1.4B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
-3%
Sundial Growers Inc
NASDAQ:SNDL
Interest Income Expense
-CA$6.6m
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Interest Income Expense
$60.9m
CAGR 3-Years
-1%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Interest Income Expense
-CA$43.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Interest Income Expense
-$141m
CAGR 3-Years
-65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
554.4m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
3.7 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Interest Income Expense?
Interest Income Expense
7.4m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Interest Income Expense amounts to 7.4m USD.

What is Mind Medicine (MindMed) Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
245%

Over the last year, the Interest Income Expense growth was 58%. The average annual Interest Income Expense growth rates for Mind Medicine (MindMed) Inc have been 245% over the past three years .

Back to Top